These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 35833245)
1. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months. De Wel B; De Schaepdryver M; Poesen K; Claeys KG Ann Clin Transl Neurol; 2022 Aug; 9(8):1241-1251. PubMed ID: 35833245 [TBL] [Abstract][Full Text] [Related]
2. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen. Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417 [TBL] [Abstract][Full Text] [Related]
3. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243 [TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience. Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971 [TBL] [Abstract][Full Text] [Related]
5. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160 [TBL] [Abstract][Full Text] [Related]
6. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067 [TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen. Andrés-Benito P; Vázquez-Costa JF; Ñungo Garzón NC; Colomina MJ; Marco C; González L; Terrafeta C; Domínguez R; Ferrer I; Povedano M Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612621 [TBL] [Abstract][Full Text] [Related]
8. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M; J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549 [TBL] [Abstract][Full Text] [Related]
10. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1-3 patients treated with nusinersen. Šimić G; Vukić V; Babić M; Banović M; Berečić I; Španić E; Zubčić K; Golubić AT; Barišić Kutija M; Merkler Šorgić A; Vogrinc Ž; Lehman I; Hof PR; Sertić J; Barišić N CNS Neurosci Ther; 2024 Mar; 30(3):e14051. PubMed ID: 36513962 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy. Kobayashi Y; Ishikawa N; Tateishi Y; Izumo H; Eto S; Eguchi Y; Okada S Brain Dev; 2023 Jan; 45(1):2-7. PubMed ID: 36210235 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen. Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963 [TBL] [Abstract][Full Text] [Related]
13. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen. Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515 [TBL] [Abstract][Full Text] [Related]
15. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study. Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J; Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen. Seo G; Kim S; Byun JC; Kwon S; Lee YJ Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812 [TBL] [Abstract][Full Text] [Related]
17. Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy. Zhang Q; Hong Y; Brusa C; Scoto M; Cornell N; Patel P; Baranello G; Muntoni F; Zhou H Sci Rep; 2024 Oct; 14(1):23491. PubMed ID: 39379509 [TBL] [Abstract][Full Text] [Related]
18. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Wurster CD; Günther R; Steinacker P; Dreyhaupt J; Wollinsky K; Uzelac Z; Witzel S; Kocak T; Winter B; Koch JC; Lingor P; Petri S; Ludolph AC; Hermann A; Otto M Ther Adv Neurol Disord; 2019; 12():1756286419846058. PubMed ID: 31205491 [TBL] [Abstract][Full Text] [Related]
19. Changes in pNFH Levels in Cerebrospinal Fluid and Motor Evolution after the Loading Dose with Nusinersen in Different Types of Spinal Muscular Atrophy. Badina M; Bejan GC; Sporea C; Padure L; Mirea A; Leanca MC; Axente M; Grigoras FP; Bejan M; Shelby ES; Neagu E; Ion DA Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512056 [No Abstract] [Full Text] [Related]
20. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen. Trifunov S; Natera-de Benito D; Carrera-García L; Codina A; Expósito-Escudero J; Ortez C; Medina J; Torres Alcala S; Bernal S; Alias L; Badosa C; Balsells S; Alcolea D; Nascimento A; Jimenez-Mallebrera C J Neuromuscul Dis; 2023; 10(4):653-665. PubMed ID: 37038823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]